<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82271">
  <stage>Registered</stage>
  <submitdate>7/09/2007</submitdate>
  <approvaldate>13/09/2007</approvaldate>
  <actrnumber>ACTRN12607000465459</actrnumber>
  <trial_identification>
    <studytitle>Permissive Hypercapnia, Alveolar Recruitment and Limited Airway Pressures reduce injury in Acute Respiratory Distress Syndrome.</studytitle>
    <scientifictitle>A phase II randomised controlled trial in acute respiratory distress syndrome of permissive hypercapnia, alveolar recruitment and limited airway pressures to determine effects on inflammatory cytokines.</scientifictitle>
    <utrn />
    <trialacronym>PHARLAP</trialacronym>
    <secondaryid>N/A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute respiratory distress syndrome.</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Initial setup: After randomization the patient will receive a stepwise recruitment manoeuvre followed by a decrimental positive end expiratory pressure (PEEP) trial commencing at 25cmH20 to determine the optimal PEEP for that patient.  Plateau airway pressures will then be reduced until either the tidal volume is &lt; 4ml/Kg, a PaCO2 &gt; 60mmHg in the presence of a plateau pressure under 30cmH20 or significant acidosis are encountered (pH&lt;7.15). 
Ongoing ventilator management: Recruitment manoeuvres will be performed regularly (up to 4 times per day) until the SaO2 &gt;/=95% on FiO2 =40% for 12 hours or FiO2 &gt;/=35% for 1 hour. In addition the arterial pH goal for the intervention patients: 7.15 &lt; pH &lt; 7.45 until the SaO2 &gt;/=95% on FiO2 =40% for 12 hours or FiO2 =35% for 1 hour.</interventions>
    <comparator>The control ventilation group reflects current best practice and is based on the ARMA ARDSnet study. In brief, using volume control ventilation, inspired tidal volumes will be limited to 6mls/Kg predicted body weight (PBW), a respiratory rate of 18, a peak airway pressure of 30cmH20 and a PEEP/FiO2 Chart (ARDSnet, NEJM 2000) is followed. The arterial pH goal for control patients: 7.30 &lt; pH &lt; 7.45 and ventilation, tidal volume and the administration of bicarbonate will be allowed.These treamtent goals will be targeted until the SaO2 &gt;/=95% on FiO2 =40% for 12 hours or FiO2 =35% for 1 hour.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Serum pro-inflammatory cytokine levels (IL-6).</outcome>
      <timepoint>Days 0 and 3.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum pro-inflammatory cytokine levels (sTNFR-1, IL-1B, IL-8, IL-10).</outcome>
      <timepoint>Day 0 (twice),1 ,3 ,5 , 7 and 10.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ventilator free days and mortality.</outcome>
      <timepoint>While it will be noted whether the patients is receiving mechancial ventilation daily, the number of ventilator free days will be calculated at day 28.
In addition the mortality rate at 28 days will be noted.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement of oxygenation and reduction in pulmonary shunt fraction.</outcome>
      <timepoint>Daily.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(1) Diagnosis of Acute Respiratory Distress Syndrome based on the American-European Consensus Conference criteria.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(1) Anticipated to require mechanical ventilation less than 48 hours (determined by attending physician), (2) more than 48 hours of mechanical ventilation prior to admission to the study, (3) pre-existing chronic obstructive pulmonary disease, (4) pregnancy (5) known intracranial abnormality (6) history of ventricular fibrillation or tachyarrhythmia (7) patient not for active treatment and (8) enrolment in another interventional study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sequentially numbered opaque envelopes. Patients will be stratified based on the presence of sepsis as the precipitating cause of ARDS.</concealment>
    <sequence>A computer generated randomisation matrix.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>17/09/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3004</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Intensive Care Unit, Alfred Hospital</primarysponsorname>
    <primarysponsoraddress>Commercial Road
Melbourne Prahan VIC 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Intensive Care Unit Educational Fund</fundingname>
      <fundingaddress>Commercial Road
Melbourne Prahan VIC 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Australian New Zealand Intensive Care Research Center</sponsorname>
      <sponsoraddress>Department of Epidemiology and Preventive Medicine
Monash University
89 Commercial Road
Melbourne VIC 3004</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study has been designed to assess whether a ventilation strategy which maintains alveolar patency by the application of recruitment manoeuvres and elevated PEEP and which limits airway pressures by allowing permissive hypercapnia will reduce lung injury as assessed by serum cytokine levels.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital Human Ethics Committee</ethicname>
      <ethicaddress>Commercial Road
Melbourne Prahan VIC 3004</ethicaddress>
      <ethicapprovaldate>15/08/2007</ethicapprovaldate>
      <hrec>98/07</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Alistair Nichol</name>
      <address>ANZIC-RC
Department of Epidemiology and Preventative Medicine
Monash University
Level 3
Burnet Building
89 Commercial Rd
Prahan Melbourne VIC 3004</address>
      <phone>+61 3 99030513</phone>
      <fax>+61 3 99030556</fax>
      <email>alistair.nichol@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Alistair Nichol</name>
      <address>ANZIC-RC
Department of Epidemiology and Preventative Medicine
Monash University
Level 3
Burnet Building
89 Commercial Rd
Prahan Melbourne VIC 3004</address>
      <phone>+61 3 99030513</phone>
      <fax>+61 3 99030556</fax>
      <email>alistair.nichol@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Alistair Nichol</name>
      <address>ANZIC-RC
Department of Epidemiology and Preventative Medicine
Monash University
Level 3
Burnet Building
89 Commercial Rd
Prahan Melbourne VIC 3004</address>
      <phone>+61 3 99030513</phone>
      <fax>+61 3 99030556</fax>
      <email>alistair.nichol@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>